Exicure, Inc. Common Stock
XCUR Real Time Price USDRecent trades of XCUR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by XCUR's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Jan. 19, 2021
-
Patent Title: Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Nov. 17, 2020
-
Patent Title: Anti-tnf compounds Sep. 01, 2020
-
Patent Title: Nucleic acid nanostructures with core motifs Jul. 07, 2020
-
Patent Title: Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications Oct. 08, 2019
-
Patent Title: Anti-tnf compounds Feb. 19, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of XCUR in WallStreetBets Daily Discussion
Recent insights relating to XCUR
Recent picks made for XCUR stock on CNBC
ETFs with the largest estimated holdings in XCUR
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view XCUR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.